| abstract |
The present invention relates to novel compounds of the general formula (I) and to pharmaceutical compositions containing them, and processes for their preparation. The compounds of the invention are useful in the treatment of melatoninergic system disorders. In the general formula (I), a saturated or unsaturated bond is present between positions 2 and 3, W is an oxygen atom or a sulfur atom, B is a straight or branched C 1-6 alkylene alkylene chain optionally substituted, R is exemplified a hydrocarbon radical, a hydrocarbonyl radical, R 'or -OR' radical, wherein R 'is optionally substituted alkyl radical of 1-6 carbonyl, C 1-6 alkenyl radical, 2-6 carbonyl radical, -hydrogen, optionally substituted aryl, biphenyl or optionally substituted-aryl aryl, or G1 is selected from the group consisting of halogen, C2-6 trihalogen-alkyl-sulfenyl-oxy, carboxy, carboxy, -O-CO-R1, of which R1 is inter alia substituted C 1 -C 6 -alkyl, optionally substituted C 3 -C 7 -cycloalkyl, aryl, biphenyl, or heteroaryl, G 1 is hydrogen, in which case G 11 is C 1 -C 6 -styrosulphenyl-phenyl-sulfinyl-sulfinyl; or cyanide, R1 or -CO-R1- or -O-CO-R1, wherein R1 is, inter alia, optionally substituted C 1-6 alkyl, G2 is (G20), (G21) or (G22), of which X is O or S, R 2 is hydrogen or C 1-6 alkyl. ŕ |